Assembly Biosciences, Inc. Appoints Nicole S. White as Senior Vice President of Pharmaceutical Development and Manufacturing
November 17, 2020 at 06:30 pm IST
Share
Assembly Biosciences, Inc. announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing. Dr. White brings over 20 years of experience overseeing the complexities of the chemistry manufacturing and controls process. Prior to joining Assembly Bio, Dr. White headed Process Chemistry at Gossamer Bio and led chemistry, manufacturing and controls (CMC) for multiple early- and late-stage programs in development. Prior to that she held progressive leadership roles at Gilead Sciences to advance multiple programs from Phase 1 through commercial launch and helped guide the drug substance manufacturing and global outsourcing strategy. While at Gilead, Dr. White contributed to the development and commercial launch of multiple antiviral programs including Harvoni®, Vemlidy® and Vosevi®. She obtained a PhD in Organic Chemistry from the University of California, Irvine and a BS in Chemistry from the University of California, San Diego.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Companyâs pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.